CervoMed Inc. (NASDAQ:CRVO - Free Report) - Equities research analysts at Brookline Capital Management boosted their Q1 2025 earnings per share (EPS) estimates for CervoMed in a research report issued to clients and investors on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings per share of ($0.47) for the quarter, up from their previous forecast of ($0.48). Brookline Capital Management currently has a "Strong-Buy" rating on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed's Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.75) EPS.
CervoMed (NASDAQ:CRVO - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The business had revenue of $2.16 million for the quarter, compared to analyst estimates of $1.51 million.
A number of other research analysts also recently commented on the stock. D. Boral Capital reiterated a "buy" rating and set a $10.00 price objective on shares of CervoMed in a research note on Monday, March 17th. Roth Capital upgraded CervoMed to a "strong-buy" rating in a research note on Thursday, December 5th. Canaccord Genuity Group increased their target price on CervoMed from $12.00 to $21.00 and gave the stock a "buy" rating in a report on Tuesday, March 18th. Roth Mkm boosted their price target on CervoMed from $15.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, March 18th. Finally, HC Wainwright cut CervoMed from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $27.50.
Get Our Latest Stock Report on CervoMed
CervoMed Stock Down 25.1 %
Shares of CervoMed stock traded down $3.58 on Thursday, hitting $10.71. 3,132,132 shares of the company's stock traded hands, compared to its average volume of 1,226,604. CervoMed has a 52-week low of $1.80 and a 52-week high of $25.92. The stock has a market cap of $66.08 million, a P/E ratio of -5.28 and a beta of 1.84. The firm's 50-day moving average is $3.47 and its 200 day moving average is $7.72.
Institutional Investors Weigh In On CervoMed
Several large investors have recently added to or reduced their stakes in the stock. Woodline Partners LP bought a new position in shares of CervoMed during the fourth quarter worth about $175,000. Perigon Wealth Management LLC acquired a new position in CervoMed during the 4th quarter valued at about $147,000. State Street Corp grew its position in CervoMed by 28.1% in the 3rd quarter. State Street Corp now owns 104,456 shares of the company's stock worth $1,525,000 after purchasing an additional 22,903 shares during the last quarter. Nuveen Asset Management LLC increased its stake in shares of CervoMed by 113.6% in the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock valued at $97,000 after purchasing an additional 22,104 shares during the period. Finally, Cornerstone Wealth Management LLC bought a new stake in shares of CervoMed during the fourth quarter valued at approximately $48,000. 25.15% of the stock is owned by institutional investors and hedge funds.
About CervoMed
(
Get Free Report)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Read More
Before you consider CervoMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.
While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
